Teva Pharmaceuticals announced in late August 2025 that it received FDA approval and commenced the U.S. launch of its generic version of Saxenda® (liraglutide injection), which had annual sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback